(ENZ) Enzo Biochem - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2941001024

ENZ: Proteins, Antibodies, Peptides, Small Molecules, Reagents, Kits

Enzo Biochem Inc (NYSE:ENZ) is a life sciences company specializing in the development and marketing of innovative labeling and detection technologies for biological targets. Founded in 1976 and headquartered in Farmingdale, New York, the company serves a diverse customer base including academic researchers, clinical researchers, biotechnology firms, pharmaceutical companies, and diagnostic manufacturers. Its product portfolio includes labels, dyes, antibodies, genomic probes, immunoassays, biochemicals, and proteins, which are integral to drug discovery, translational research, and drug development processes. Enzo Biochem’s technologies are utilized in various research areas such as cell biology, genomics, immunohistochemistry, and small molecule chemistry. The company also licenses its proprietary technologies to enhance research and development efforts in the life sciences industry.

Enzo Biochem’s products and services are designed to enable precise and efficient analysis in drug development and research. The company’s genomic probes and immunoassays are particularly valuable in identifying and quantifying biological targets, facilitating advancements in personalized medicine and therapeutic interventions. By providing tools for labeling, detecting, and visualizing biological targets, Enzo Biochem plays a critical role in accelerating the transition from basic research to clinical applications. Its focus on innovation and precision has established it as a trusted partner in the global life sciences industry.

Based on the provided and , the three-month forecast for Enzo Biochem Inc (NYSE:ENZ) suggests the following trends: The stock is expected to trade within a narrow range, influenced by its current price of $0.46, which is below the 20-day and 50-day moving averages of $0.50 and $0.60, respectively. The 200-day moving average of $0.91 indicates a potential long-term downtrend. The average true range (ATR) of $0.04 suggests low volatility, with price movements likely to remain constrained. From a fundamental perspective, the company’s market cap of $26.98M and price-to-book (P/B) ratio of 0.57 may indicate undervaluation relative to its book value. However, the negative return on equity (RoE) of -47.92% signals ongoing profitability challenges. Overall, the stock is expected to remain under pressure in the near term, with limited upside potential due to its weak financial performance and technical indicators pointing to bearish momentum.

Additional Sources for ENZ Stock

ENZ Stock Overview

Market Cap in USD 26m
Sector Healthcare
Industry Diagnostics & Research
GiC Sub-Industry Health Care Services
IPO / Inception 1980-06-12

ENZ Stock Ratings

Growth 5y -80.7%
Fundamental -66.7%
Dividend 36.7%
Rel. Strength Industry -57.1
Analysts -
Fair Price Momentum 0.43 USD
Fair Price DCF -

ENZ Dividends

Dividend Yield 12m 13.16%
Yield on Cost 5y 5.24%
Annual Growth 5y -100.00%
Payout Consistency 100.0%

ENZ Growth Ratios

Growth Correlation 3m -97.1%
Growth Correlation 12m -58.5%
Growth Correlation 5y -77.8%
CAGR 5y -23.53%
CAGR/Max DD 5y -0.27
Sharpe Ratio 12m -0.08
Alpha -67.31
Beta 0.98
Volatility 46.80%
Current Volume 38.2k
Average Volume 20d 97.2k
What is the price of ENZ stocks?
As of March 15, 2025, the stock is trading at USD 0.50 with a total of 38,239 shares traded.
Over the past week, the price has changed by +7.20%, over one month by -8.75%, over three months by -50.75% and over the past year by -56.73%.
Is Enzo Biochem a good stock to buy?
No, based on ValueRay Fundamental Analyses, Enzo Biochem (NYSE:ENZ) is currently (March 2025) a stock to sell. It has a ValueRay Fundamental Rating of -66.72 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ENZ as of March 2025 is 0.43. This means that ENZ is currently overvalued and has a potential downside of -14%.
Is ENZ a buy, sell or hold?
Enzo Biochem has no consensus analysts rating.
What are the forecast for ENZ stock price target?
According to ValueRays Forecast Model, ENZ Enzo Biochem will be worth about 0.5 in March 2026. The stock is currently trading at 0.50. This means that the stock has a potential downside of -2%.
Issuer Forecast Upside
Wallstreet Target Price 5.5 1000%
Analysts Target Price 5.5 1000%
ValueRay Target Price 0.5 -2%